Remove

NFORMATION DISCLOSURE	Application Number		09753537		
	Filing Date		2001-01-02		
	First Named Inventor	David L. Multer			
Not for submission under 37 CFR 1.99)	Art Unit		2165		
Not for autimission under 57 Of R 1.557	Examiner Name	Abel .	Jalii, Neveen		
	Attorney Docket Numb	or	FUSL04105		

U.S.PATENTS

Examiner Initial*	Cite No	F	Patent Number	Kind Code ¹	Issue (Date	Name of Pat of cited Doc	lentee or Applicant ument	Relev	s,Columns,Lines where vant Passages or Relev es Appear	
	1	5	758354		1998-0	5-26	Huang et al.				
	2	e	564336	B1	2003-0	5-13	Majkowski				
If you wisl	h to ac	dd a	dditional U.S. Pate	nt citatio	n inform	nation pl	ease click the	Add button.	_	Add	
				U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial* Cite No Publication Number		Kind Code ¹	Publica Date	ation	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
If you wis	1 h to ac	dd a	dditional U.S. Publ				n information	please click the Ad	d butto	n. Add	
Examiner Cite Initial* No Number3		Country Kind Code ² i Code			Publication	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Ts		
	1										
If you wisl	h to a	dd a	dditional Foreign P	atent Do	cument	citation	information p	lease click the Add	buttor	Add	_
				NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	Ţs	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1.5ee KinG Codes of USPTO Patient Documents at year LISETQ.CQQ or MRCP 901.64. ² Exits office that issued the document, by the how-left code (WIPO Standard ST3), ³ For Japanese patient Concurrent, by including the party of the Emprover may precede the existent number of the patient counternt, ⁴ Kind of countent by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ³ Applicant is to place a check mark here if English language in translation in attacker.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09753537	
Filing Date		2001-01-02	
First Named Inventor	David L. Multer		
Art Unit		2165	
Examiner Name	Abel .	Abel Jalii, Neveen	
Attorney Docket Number		FUSI-04105	

CERTIFICATION STATEMENT

Please see 37	CFR 1	.97 and	1.98 to make the	appropriate	selection(s)	
---------------	-------	---------	------------------	-------------	------------	----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no learn of information contained in the information disclosure statement was clied in a communication from a foreign patient office in a counterpart froming neglication, and to the knowledge of the perion signing the centification after making reasonable inquiry, no learn of information contained in the information disclosure statement was known to after any individual designated in 37 CFR 156tic more than three months poir to the filling of the information disclosure.

statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

David A Hill

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.	orm of the signature.								
Signature	/David A. Hill/	Date (YYYY-MM-DD)	2012-03-06						

Registration Number

44 153

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. O. Box 1450, Alexandri, V.S. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2213-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicided to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested process and or examine your submission related to a patient application or patient. If you do not furnish the requested remaining the processing of the patient processing or the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.